High effectiveness of durvalumab consolidation in stage-III NSCLC: Focus on treatment selection and prognostic factors. Supplementary Tables

<strong>Supplement Table 1:</strong> Pre-radiotherapy characteristics as possible confounders used for propensity score weighting after balancing. Inverse probability weighted counts are shown for ordinal or dichotomous data and the median of the weighted distribution is shown for continuous variables. Counts were shown as nearest integer values. <strong>Supplementary Table 2</strong> <br> Univariable proportional hazard analysis of the covariables shown in Table 1 in the group of patients with durvalumab or without durvalumab consolidation CBDCA: carboplatin